Deterioration of Visual Acuity after Brachytherapy and Proton Therapy of Uveal Melanoma, and Methods of Counteracting This Complication Based on Recent Publications.
brachytherapy
proton therapy
radiation complications
radiation therapy
uveal melanoma
vision deterioration
visual acuity
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
12 Jun 2023
12 Jun 2023
Historique:
received:
04
04
2023
revised:
30
05
2023
accepted:
07
06
2023
medline:
29
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. The eyeball is the most common extracutaneous location of melanoma. UM is a huge threat to a patient's life. It metastasizes distantly via blood vessels, but it can also spread locally and infiltrate extraocular structures. The treatment uses surgical methods, which include, among others, enucleation and conservative methods, such as brachytherapy (BT), proton therapy (PT), stereotactic radiotherapy (SRT), stereotactic radiosurgery (SRS), transpupillary thermotherapy (TTT) and photodynamic therapy. The key advantage of radiotherapy, which is currently used in most patients, is the preservation of the eyeball with the risk of metastasis and mortality comparable to that of enucleation. Unfortunately, radiotherapy very often leads to a significant deterioration in visual acuity (VA) as a result of radiation complications. This article is a review of the latest research on ruthenium-106 (Ru-106) brachytherapy, iodine-125 (I-125) brachytherapy and proton therapy of uveal melanoma that took into account the deterioration of eye function after therapy, and also the latest studies presenting the new concepts of modifications to the applied treatments in order to reduce radiation complications and maintain better visual acuity in treated patients.
Identifiants
pubmed: 37374335
pii: medicina59061131
doi: 10.3390/medicina59061131
pmc: PMC10303310
pii:
doi:
Substances chimiques
Iodine-125
GVO776611R
Iodine Radioisotopes
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
J Contemp Brachytherapy. 2019 Dec;11(6):554-562
pubmed: 31969914
Cureus. 2019 Jul 29;11(7):e5270
pubmed: 31576263
Acta Oncol. 2021 Feb;60(2):207-214
pubmed: 32969745
JAMA Ophthalmol. 2020 Feb 1;138(2):136-146
pubmed: 31830238
Clin Ter. 2020 Jan-Feb;170(1):e89-e98
pubmed: 31916427
Cancer Radiother. 2022 Nov;26(8):1016-1026
pubmed: 35803860
Arch Ophthalmol. 2001 May;119(5):670-6
pubmed: 11346394
J Contemp Brachytherapy. 2021 Jun;13(3):358-364
pubmed: 34122577
JAMA Ophthalmol. 2018 Sep 1;136(9):981-986
pubmed: 29955797
PLoS One. 2020 Dec 2;15(12):e0242966
pubmed: 33264363
Asia Pac J Ophthalmol (Phila). 2017 Mar-Apr;6(2):186-196
pubmed: 28399342
Drugs. 2022 Apr;82(6):703-710
pubmed: 35364798
Graefes Arch Clin Exp Ophthalmol. 2022 Apr;260(4):1337-1343
pubmed: 34735632
Radiother Oncol. 2022 Nov;176:39-45
pubmed: 36184996
Ophthalmology. 1986 May;93(5):666-74
pubmed: 3014415
Cancers (Basel). 2021 Dec 13;13(24):
pubmed: 34944862
Klin Monbl Augenheilkd. 2002 Apr;219(4):211-5
pubmed: 12022003
Arch Ophthalmol. 2006 Dec;124(12):1684-93
pubmed: 17159027
J Contemp Brachytherapy. 2021 Aug;13(4):433-440
pubmed: 34484358
J Contemp Brachytherapy. 2018 Dec;10(6):532-541
pubmed: 30662476
Clin Ophthalmol. 2020 Feb 04;14:339-346
pubmed: 32099319
Eye (Lond). 2012 Nov;26(11):1487-9
pubmed: 22935669
Ophthalmology. 2021 Jan;128(1):152-161
pubmed: 32574763
Phys Med. 2022 Sep;101:71-78
pubmed: 35981450
Cancers (Basel). 2022 Jun 01;14(11):
pubmed: 35681733
Cancer Control. 2004 Sep-Oct;11(5):304-9
pubmed: 15377989
Br J Ophthalmol. 2020 May;104(5):697-702
pubmed: 31409650
Arch Ophthalmol. 2000 Sep;118(9):1219-28
pubmed: 10980767
Am J Clin Oncol. 2021 Jan 1;44(1):32-42
pubmed: 33208706
Nat Rev Dis Primers. 2020 Apr 9;6(1):24
pubmed: 32273508
N Engl J Med. 2021 Sep 23;385(13):1196-1206
pubmed: 34551229
Invest Ophthalmol Vis Sci. 2021 Jan 4;62(1):3
pubmed: 33393969
Radiother Oncol. 2022 Jan;166:15-25
pubmed: 34774654
BMC Ophthalmol. 2022 Jul 16;22(1):309
pubmed: 35842619
Cesk Slov Oftalmol. 2020 Fall;77(1):1-13
pubmed: 33086849
Med Phys. 2019 Feb;46(2):1006-1011
pubmed: 30554429
Brachytherapy. 2014 Jan-Feb;13(1):1-14
pubmed: 24373763
Acta Ophthalmol. 2022 Aug;100(5):511-519
pubmed: 34529346
Asia Pac J Ophthalmol (Phila). 2020 Jan-Feb;9(1):29-38
pubmed: 31990743
Front Oncol. 2022 Jan 03;11:754108
pubmed: 35047387
Radiother Oncol. 2022 Sep;174:16-22
pubmed: 35788353
Cancers (Basel). 2023 Jan 04;15(2):
pubmed: 36672282
Ophthalmic Res. 2022 Mar 31;:
pubmed: 35358966
Ocul Oncol Pathol. 2021 Jun;7(3):159-167
pubmed: 34307326
Curr Opin Ophthalmol. 2021 May 1;32(3):183-190
pubmed: 33770014
Arch Ophthalmol. 2010 Jul;128(7):888-93
pubmed: 20625051
J Clin Med. 2022 Apr 12;11(8):
pubmed: 35456233
Ophthalmology. 2001 Feb;108(2):348-66
pubmed: 11158813
Int J Clin Exp Pathol. 2013 Jun 15;6(7):1230-44
pubmed: 23826405
Med Phys. 2021 Aug;48(8):4542-4559
pubmed: 34250607
Br J Ophthalmol. 2021 Jan;105(1):57-62
pubmed: 32430342
Ocul Oncol Pathol. 2017 Sep;3(3):193-198
pubmed: 29071269
Eye (Lond). 2023 Apr;37(5):959-965
pubmed: 35140328